NCT02511223View on ClinicalTrials.gov

Efficacy and Safety of PARPi to Treat Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

April 18, 2021

Study Completion Date

April 18, 2021

Conditions
Pancreatic Cancer
Interventions
DRUG

OLAPARIB

Olaparib 300 (mg) twice a day per os given every day until disease progression or toxicity

Trial Locations (1)

Unknown

Sheba Medical Centre, Ramat Gan

All Listed Sponsors
lead

Sheba Medical Center

OTHER_GOV

NCT02511223 - Efficacy and Safety of PARPi to Treat Pancreatic Cancer | Biotech Hunter | Biotech Hunter